Supplementary Table 1 from PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with &lt;i&gt;EGFR&lt;/i&gt; and &lt;i&gt;ERBB2&lt;/i&gt; Mutations that Are Resistant to Gefitinib